CD4 and cancer: The above studies showing an IL-23 signaling-dependent decline in spleen cell production of IFN-γ -expressing CD4+ cells as lesions progress to cancer with a concurrent increase in spleen cell production of IL-10 prompted studies to determine the levels of Treg in wildtype and IL-23R KO mice.